Effectiveness and safety of remimazolam tosilate versus propofol in patients undergoing painless gastrointestinal endoscopy: A randomized controlled trial.

Author:

Li Dong-Bin1,Wang Yu1,Xing Yang1,Zhao Zi-Cen1,Chang Li-Ya1,Leng Yu-Fang2ORCID

Affiliation:

1. Lanzhou University

2. Lanzhou University First Hospital

Abstract

Abstract

Background Remimazolam tosilate and propofol are commonly used sedatives. However, there are few reports that compare the effectiveness and safety of remimazolam with those of propofol combined with alfentanil. Aim This trial compared the effectiveness and safety of remimazolam with those of propofol in patients undergoing painless gastrointestinal endoscopy. Methods One hundred and sixty-six eligible patients who underwent painless gastrointestinal endoscopy under intravenous anaesthesia were randomly divided into 2 groups: the propofol control group (Group P) and the remimazolam group (Group R). The primary outcomes were perioperative haemodynamic variables. The secondary outcomes included induction and awakening time, patient satisfaction, operator satisfaction, drug injection pain, hypoxemia, hypotension, bradycardia, limb movement, hiccups, postoperative nausea and vomiting, and 4 times or more drug additions. Results Compared with those in Group P, the SBP in Group R was significantly higher at T1, T2, T3, and T6 (P < 0.05); the DBP and MAP were significantly higher at T1, T2, T3, T5, and T6 (P < 0.05); the HR was significantly faster at T1 to T6 (P < 0.05); the SpO2 was significantly higher at T1 to T4 (P < 0.05); the incidences of intraoperative hypoxemia, hypotension, and drug injection pain were significantly lower in Group R (P < 0.05); the incidence of intraoperative hiccups was higher (P < 0.05); the awakening time was shorter in Group R (P < 0.05); and the operator satisfaction score was high (P < 0.05). Conclusions Remimazolam, in combination with alfentanil, is utilized for painless gastrointestinal endoscopy,which has a short awakening time, minimal circulatory and respiratory effects, and low incidence of adverse events. Clinical trial registration This trial protocol was registered in the Chinese Clinical Trial Registry (ChiCR2300077252, date: 2023 11 02)

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3